Aptus Pharma IPO is a book-built issue aiming to raise ₹13.02 crore. It comprises a fresh issue of 0.186 crore shares aggregating to ₹13.02 crore. The bidding window was open from September 23, 2025, to September 25, 2025, with the IPO allotment to be finalised on September 26, 2025. Aptus Pharma is scheduled to list on BSE SME on September 30, 2025.
The IPO was priced at ₹65–₹70 per share with a lot size of 2,000 shares (minimum retail investment ₹2.80 lakh at the upper band). The public issue received bids for 2,75,72,000 shares against 12,38,000 shares available, resulting in an overall subscription of 22.27 times. Retail investors subscribed 31.43 times, NIIs 28.75 times, and QIBs 1.24 times.
Aptus Pharma’s ₹13.02 crore IPO, priced at ₹65–₹70 per share, was subscribed 22.27 times overall. The IPO consists entirely of a fresh issue of 0.186 crore shares aggregating to ₹13.02 crore. Bidding took place from September 23 to September 25, 2025, with the IPO allotment status finalised on September 26, 2025. Retail investors subscribed 31.43 times, NIIs 28.75 times, while QIBs subscribed 1.24 times. Listing is expected on September 30, 2025, on BSE SME.
The table below breaks down the Aptus Pharma share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| Investor Category | Shares Offered |
| Market Maker | 94,000 (5.05%) |
| QIB | 8,80,000 (47.31%) |
| NII (HNI) | 2,66,000 (14.30%) |
| Retail Investors (RII) | 6,20,000 (33.33%) |
| Total | 18,60,000 (100.00%) |
| Category | Subscription (times) |
| QIB (Ex Anchor) | 1.24 |
| NII* | 28.75 |
| └─ bNII (bids above ₹10L) | 30.64 |
| └─ sNII (bids below ₹10L) | 24.93 |
| Individual Investors (RII) | 31.43 |
| Total | 22.27 |
Note: The subscription details are as of September 25, 2025
Aptus Pharma Ltd, incorporated in 2010, is engaged in the marketing and distribution of finished pharmaceutical formulations. The company offers a wide range of products across multiple therapeutic segments, including antacids and PPIs, pain management, anti-inflammatories, antibiotics, cardiology, antidiabetics, neuropsychiatry, dental care, injectable parenterals, syrups, nutraceuticals, sachets, and more.
Its product lines are structured under different verticals: Aptus Pharma, which caters to acute therapies such as anti-infectives and pain management; Aptus CD Care, focused on chronic therapies; Aptus Wellcare, which provides wellness and nutraceutical solutions; and Aptus Global, dedicated to international markets.
As of March 31, 2025, the company had 194 formulations spanning over eleven therapeutic areas. Aptus Pharma operates with warehouse facilities in Ahmedabad, Gujarat, covering more than 17,700 sq. ft. and maintains a distribution network of 125 direct and sub-distributors supported by a field sales team of 54 professionals. With a workforce of 70 employees, the company’s strengths lie in its diversified product portfolio, strong distribution network, strategic manufacturing partnerships in Gujarat, Uttarakhand, and Himachal Pradesh, competitive pricing, and experienced management team.
Track your IPO allotment status and access your application online to get the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Sep 25, 2025, 10:34 PM IST
Kusum Kumari
Kusum Kumari is a Content Writer with 4 years of experience in simplifying financial market concepts. Currently crafting insightful content at Angel One, She specialise in breaking down complex topics into easy-to-understand pieces, blending expertise in market fundamentals and technical analysis.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
